Study of Gemcitabine, Oxaliplatin, and Paclitaxel in Patients With Refractory Germ Cell Carcinoma
2期
已完成
NCT00183820
| 适应症 | Testicular Cancer, Germ Cell Neoplasm |
|---|
| 分期 | 2期 |
|---|
| 申办方 | University of Southern California |
|---|
| 状态 | 已完成 |
|---|
| 受试者人数 | 30 人 |
|---|
| 干预（药物） | paclitaxel, gemcitabine, and oxaliplatin |
|---|
| 开始日期 | 2004年11月 |
|---|
| 完成日期 | 2015年12月 |
|---|
| 结果公布日 | 2026年7月1日 |
|---|
摘要
This is a study for patients with advanced testicular cancer. This research study involves treatment with oxaliplatin, paclitaxel, and gemcitabine, which is an investigational chemotherapy combination. This study is for patients who have not responded to standard cisplatin-containing chemotherapy or the cancer has returned after such treatment. This research is being done to assess the effectiveness of the proposed combination of medications for this type of cancer.
Tumor Response
From start of study drug until the date of first documented progression or date of death from any cause, whichever came first, assessed every 6 weeks, through study completion, up to 9 years · Participants
| Paclitaxel, Gemcitabine, and Oxaliplatin | 2 Participants |
|---|
| Paclitaxel, Gemcitabine, and Oxaliplatin | 7 Participants |
|---|
| Paclitaxel, Gemcitabine, and Oxaliplatin | 15 Participants |
|---|
| Paclitaxel, Gemcitabine, and Oxaliplatin | 5 Participants |
|---|
在 BENITIONS 中查看
查看 ClinicalTrials.gov 原文
全部试验
本页整理自 ClinicalTrials.gov 的公开数据，不构成医疗建议，也不构成投资建议。请务必咨询专业医师。